Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Panelists discuss advanced renal cell carcinoma (RCC), including its epidemiology, typical disease presentation, and the common patient profile in terms of age, gender, and family history, while also addressing the risk stratification for advanced RCC, highlighting the differences between ...
“We really want to understand whether by using this beta emitter, together with the combination of cabazantinib and the nivolumab, we're getting better outcomes than we would expect with the doublet alone,” says Eric Jonasch, MD.
In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating belzutifan for advanced clear cell renal cell carcinoma treatment.
Neoadjuvant therapy for high-risk renal cell carcinoma (RCC) may offer a survival advantage over adjuvant therapy, according to data presented at ...
Dostarlimab achieved a 100% clinical complete response rate in patients with dMMR/MSI-H advanced rectal cancer, a phase 2 study found.
A final decision on marketing authorization is anticipated for Q1 of 2025.
The EMA’s CHMP has recommended the approval of belzutifan monotherapy for patients with select VHL disease–associated cancers.
ALLO-316, a CD70-targeting CAR T-cell therapy, has demonstrated activity in patients with previously treated, advanced ccRCC.
A study now reports that Cu, as a subunit of cytochrome c oxidase (CuCOX), promotes the development of clear cell renal cell carcinoma (ccRCC) through ...
“We did see that there was a certain percentage of individuals who had to have dose holding, and a smaller percentage of people had to have dose reduction, in general,” says Eric Jonasch, MD.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.